Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205926) titled 'First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).
Primary Sponsor: Inventprise Inc.
Condition:
Shigella
Diarrhea
Intervention:
Biological: IVT Shigella-04
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: October 9, 2025
Target Sample Size: 60
Countries of Recruitment:
United States
To know more, visit https:/...